In March 2005 the FDA approved Symlin (pramlintide acetate).

In March 2005 the FDA approved Symlin (pramlintide acetate), an injectable medicine to regulate blood sugar for adults with mark 1 and type 2 diabetes. Symlin is the single therapy for treating type 1 diabetes other than insulin. clan with type 2 diabetes already have several other adumbrations of oral therapies available.

Symlin is to be used alone in combination with insulin to help lower descendants sugar during the three hours after meals. It is meant for patients who cannot achieve adequate house sugar control on intensive insulin therapy alone. So-called "tight" regulate of blood sugar is desirable in all patients with diabetes to form the risk of blindness, kidney disease, vascular disease, and other long-term moot points that diabetes can cause.

The safety and effectiveness of Symlin were studied in about 5000 race Side effects include nausea, vomiting, abdominal pain, headache, fatigue, and dizziness. Because of three areas of pertain to there will be a medication guide and a risk minimization action plan for the use of Symlin. First, the principal risk is hypoglycemia, an abnormally grave concentration of sugar in the progeny This risk is greatest in populace with type i diabetes and the public with slow stomach emptying (gastroparesis), a long-term complication of diabetes. other there is a potential for medication errors, specifically, mixing Symlin with insulin in the same syringe, which can alter the activity of the insulin. Finally, the potential for off-label use in folks where the benefit-risk profile has not been characterized or demonstrated is also of matter and will be monitored by the agency of the sponsor.

Symlin has not been evaluated in children. The therapy should not be used if nation cannot tell when their kin sugar is low, have gastroparesis, or are allergic to pramlintide acetate, metacresol, D-mannitol, acetic acid, or sodium acetate.

Symlin is manufactured at Amylin Pharmaceuticals Inc. of San Diego.

...

Home